Molecure (WAR:MOC) EPS without NRI: zł-1.03 (TTM As of Sep. 2025)


WAR:MOC Molecure SA WAR:MOC
30 GF Score
Price zł5.92
! 3 Warning Signs
View Full Analysis

What is Molecure EPS without NRI?

Molecure WAR:MOC +4.41% 30 EPS without NRI is zł-1.03 as of Sep. 2025. GuruFocus rates WAR:MOC with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,167 Biotechnology companies, Molecure ranks worse than 83.98% on this metric.

Molecure's earnings per share without non-recurring items for the three months ended in Sep. 2025 was zł-0.31. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2025 was zł-1.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Molecure's EPS without NRI or its related term are showing as below:

WAR:MOC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -100.4   Med: -43.7   Max: -8.9
Current: -16.5

WAR:MOC's 3-Year EPS without NRI Growth Rate is ranked worse than
83.98% of 1167 companies
in the Biotechnology industry
Industry Median: 16.2 vs WAR:MOC: -16.50

Molecure's EPS (Diluted) for the three months ended in Sep. 2025 was zł-0.31. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was zł-1.03.

Molecure's EPS (Basic) for the three months ended in Sep. 2025 was zł-0.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2025 was zł-1.03.


Molecure  (WAR:MOC) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Molecure EPS without NRI Related Terms


Molecure EPS without NRI Historical Data

* Premium members only.

The historical data trend for Molecure's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecure EPS without NRI Chart

Molecure Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.90 -0.98 -1.09 -1.69 -1.55

Molecure Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.37 -0.31 -0.26 -0.15 -0.31

WAR:MOC vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Molecure's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecure PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecure's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Molecure's PE Ratio without NRI falls into.


WAR:MOC
30GF Score
Molecure SA WAR:MOC
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecure EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-1.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of zł-1.03 mean?
Molecure (WAR:MOC) has a EPS without NRI of zł-1.03 as of Sep. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Molecure and its competitors. According to the industry distribution chart, Molecure ranks #980 out of 1167 companies in the Biotechnology industry, placing it in the top 84%.
Is Molecure's EPS without NRI too high?
Molecure's current EPS without NRI is zł-1.03. Based on the distribution chart, Molecure ranks #980 out of 1167 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Molecure has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Molecure's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecure ranks #980 out of 1167 companies for EPS without NRI. This places Molecure in the lower half of its industry. The industry median EPS without NRI is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.20, based on 1,167 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Molecure and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecure's current EPS without NRI is zł-1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecure stock overvalued right now?
Molecure (WAR:MOC) has a current EPS without NRI of zł-1.03. The current EPS without NRI is zł-1.03. Molecure's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Molecure (WAR:MOC), the current EPS without NRI is zł-1.03 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Molecure Business Description

Other Exchanges 1B1:Germany
Address Zwirki i Wigury 101, Warsaw, POL, 02-089
Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.
30GF Score

Get the complete analysis for WAR:MOC

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł5.92
Price